HER2-targeted therapies are associated with cardiotoxicity which is usually asymptomatic and reversible. We report the updated cardiac safety assessment of patients with compromised heart function receiving HER2-targeted therapy for breast cancer, enrolled in the SAFE-HEaRt trial, at a median follow-up of 3.5 years.
Thirty patients with stage I-IV HER2-positive breast cancer receiving trastuzumab with or without pertuzumab, or ado-trastuzumab emtansine (T-DM1), with asymptomatic LVEF (left ventricular ejection fraction) 40–49%, were started on cardioprotective medications, with the primary endpoint being completion of HER2-targeted therapy without cardiac events (CE) or protocol-defined asymptomatic worsening of LVEF. IRB-approved follow-up assessment included 23 patients.
Median follow-up as of June 2020 is 42 months. The study met its primary endpoint with 27 patients (90%) completing their HER2-targeted therapies without cardiac issues. Of the 23 evaluable patients at long-term f/u, 14 had early stage breast cancer, and 9 had metastatic disease, 8 of whom remained on HER2-targeted therapies. One patient developed symptomatic heart failure with no change in LVEF. There were no cardiac deaths. The mean LVEF improved to 52.1% from 44.9% at study baseline, including patients who remained on HER2-targeted therapy, and those who received prior anthracyclines.
Long-term follow-up of the SAFE-HEaRt study continues to provide safety data of HER2-targeted therapy use in patients with compromised heart function. The late development of cardiac dysfunction is uncommon and continued multi-disciplinary oncologic and cardiac care of patients is vital for improved patient outcomes.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Steingart RM, Yu AF, Dang CT (2019) Trastuzumab cures cancer and disrupts the practice of cardiology∗. JACC: CardioOncol 1:11–13. https://doi.org/10.1016/j.jaccao.2019.06.002
Mazzotta M, Krasniqi E, Barchiesi G et al (2019) Long-term safety and real-world effectiveness of trastuzumab in breast cancer. J Clin Med 8:254. https://doi.org/10.3390/jcm8020254
Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811–7819. DOI:23/31/7811 [pii]
Perez EA (2008) Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 8(Suppl 3):114. DOI:S1526-8209(11)70932-6 [pii]
Milano G, Chamorey E, Ferrero JM (2016) Trastuzumab and cardiac outcomes in breast cancer: a story we know by heart? JAMA Oncol 2:21–22. https://doi.org/10.1001/jamaoncol.2015.3866
Chien AJ, Rugo HS (2010) The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 9:335–346. https://doi.org/10.1517/14740331003627441
Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792–3799. https://doi.org/10.1200/JCO.2011.40.0010
Seferina SC, de Boer M, Derksen MW et al (2016) Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily dutch practice: a study of the southeast Netherlands breast cancer consortium. Oncologist 21:555–562. https://doi.org/10.1634/theoncologist.2015-0230
Ganz PA, Romond EH, Cecchini RS et al (2017) Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol 35:3942–3948. https://doi.org/10.1200/JCO.2017.74.1165
Sendur MA, Aksoy S, Altundag K (2013) Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 29:1015–1024. https://doi.org/10.1185/03007995.2013.807232
Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177:237–250. https://doi.org/10.1007/s10549-019-05303-y
Lidbrink E, Chmielowska E, Otremba B et al (2019) A real-world study of cardiac events in >3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat 174:187–196. https://doi.org/10.1007/s10549-018-5058-6
Sardesai S, Sukumar J, Kassem M et al (2020) Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardio-Oncology 6:26. https://doi.org/10.1186/s40959-020-00081-9
Rushton M, Lima I, Tuna M et al (2020) Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada. J Natl Cancer Inst:djaa054. https://doi.org/10.1093/jnci/djaa054
Barron CC, Alhussein MM, Kaur U et al (2019) An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. Curr Oncol 26. https://doi.org/10.3747/co.26.4631
Yu AF, Yadav NU, Eaton AA et al (2015) Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist 20:1105–1110. https://doi.org/10.1634/theoncologist.2015-0125
Barron CC, Tyagi NK, Alhussein MM et al (2019) Adjuvant trastuzumab therapy: can we balance efficacy and safety? Oncologist 24:1405–1409. https://doi.org/10.1634/theoncologist.2019-0263
Anonymous Herceptin [package insert]. San Francisco, CA: Genentech, Inc., 2015
Anonymous Kadcyla [package insert]. San Francisco, CA: Genentech, Inc., 2016
Anonymous Perjeta [package insert]. San Francisco, CA: Genentech, Inc., 2016
Lynce F, Barac A, Tan MT et al (2017) SAFE-HEaRt: rationale and design of a pilot study investigating cardiac safety of HER2 targeted therapy in patients with HER2-positive breast cancer and reduced left ventricular function. Oncologist 22:518–525. https://doi.org/10.1634/theoncologist.2016-0412
Lynce F, Barac A, Geng X et al (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175:595–603. https://doi.org/10.1007/s10549-019-05191-2
Leong DP, Cosman T, Alhussein MM et al (2019) Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial. JACC: CardioOncol 1:1–10. https://doi.org/10.1016/j.jaccao.2019.06.004
Banke A, Fosbøl EL, Ewertz M et al (2019) Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 7:217–224
Hayek SS, Ganatra S, Lenneman C et al (2019) Preparing the cardiovascular workforce to care for oncology patients: JACC review topic of the week. J Am Coll Cardiol 73:2226–2235
Alvarez-Cardona JA, Ray J, Carver J et al (2020) Cardio-oncology education and training: JACC council perspectives. J Am Coll Cardiol 76:2267–2281
Rassaf T, Totzeck M, Backs J et al (2020) Onco-cardiology: consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol 109:1197–1222. https://doi.org/10.1007/s00392-020-01636-7
López-Fernández T (2020) Cardiac imaging in oncology patients in Europe: a model for advancement of CV safety and development of comprehensive CV care. J Cardiovasc Transl Res 13:490–494. https://doi.org/10.1007/s12265-020-10028-1
This work was supported by Genentech, Inc., a member of the Roche group [ML28685]; the National Cancer Institute at the National Institutes of Health [P30CA051008 to Site P.I., L.M. Weiner]; a Conquer Cancer Foundation of ASCO Young Investigator Award, supported by The Breast Cancer Research Foundation [F.L.]; a Georgetown-Howard Universities Center for Clinical & Translational Science Post-doctoral KL2 Award [A.B.]; and Genentech, Inc. provided study drugs: ado-trastuzumab emtansine (T-DM1), pertuzumab, and trastuzumab in-kind. Any opinions, findings, and conclusions expressed in this work are those of the authors and do not necessarily reflect those of the American Society of Clinical Oncology, the Conquer Cancer Foundation, The Breast Cancer Research Foundation, the National Cancer Institute at the National Institutes of Health, or the National Institutes of Health.
Conflict of interest
K. Khoury, X. Geng, R. Warren, M. Srichai, M. Hofmeyer, and F. Asch, report no competing interests. F. Lynce reports consulting/advisory role from Bristol-Myers Squibb, Jounce Therapeutics (unpaid), AstraZeneca and Pfizer/EMD Serono, association with the speakers’ bureau for ASCO, travel, accommodations and expenses from Bristol-Myers Squibb and Genentech, has received research funding from Pfizer, Bristol-Myers Squibb and Inivata, and institution-associated research funding from Calithera Biosciences, Immunomedics, Chugai Pharma USA, Regeneron, Inivata, and Tesaro. A. Barac reports consulting/advisory role from Takeda Science Foundation. C. Dang reports consulting/advisory role and travel, accommodations and expenses and has received honoraria from Genentech/Roche, Puma Biotechnology, Lilly, and has received research institution-associated funding from Genentech/Roche and Puma Biotechnology. A. Yu reports consulting/advisory role from AstraZeneca and Genentech for himself and an immediate family member, and research funding from AstraZeneca received for an immediate family member. K. Smith reports stock and ownership interest in Abbvie and Abbott laboratories, and has received institution-associated funding from Pfizer. C. Gallagher reports consulting/advisory role from Seattle Genetics, and association with the speakers’ bureau for Daiichi-Sankyo. P. Pohlmann reports consulting/advisory role from Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, Puma Biotechnology, Sirtex Medical, Caris Life Sciences, SeaGen and Juniper, association with the speakers’ bureau for Genentech/Roche, patents: United States Patent no. 8,486,413, United States Patent no. 8,501,417, United States Patent no. 9,023,362, United States Patent no. 9,745,377, stock/ownership and leadership in Immunonet BioSciences, received honoraria from ASCO and Dava Oncology, and institution-associated research funding from Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, BOLT, SeaGen, Byondis, and Cascadian Therapeutics. R. Nunes reports consulting/advisory role from Agendia (unpaid), and has received research funding from bioTheranostics. P. Herbolsheimer is an employee of AstraZeneca, and reports travel, accommodations and expenses and stock/ownership from AstraZeneca. M. Tan reports consulting/advisory role from American Gene Technologies, has received honoraria from AstraZeneca, Incyte, Otsuka, and Sanofi Pasteur, travel and accommodations from Otsuka, and research funding from Genentech. C. Isaacs reports consulting/advisory role from Pfizer, Genentech/Roche, Novartis, AstraZeneca, Puma Biotechnology, Context Therapeutics, and Seattle Genetics, association with the speakers’ bureau for Genentech, Pfizer, and AstraZeneca, received honoraria from Genentech/Roche, AstraZeneca, and Pfizer, and institution-associated research funding from Novartis, Pfizer, Genentech, and Tesaro. S. Swain reports consulting/advisory or non promotional speaking role from Exact Sciences (Genomic Health), Genentech/Roche, Daiichi Sankyo, Athenex, Natura, and Silverback Therapeutics, IDMC from AstraZeneca, support for third party writing assistance from Genentech/Roche, and institution-associated research funding from Genentech and Kailos Genetics. The COI’s described above include competing interests of greater than 1 year.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Khoury, K., Lynce, F., Barac, A. et al. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat 185, 863–868 (2021). https://doi.org/10.1007/s10549-020-06053-y
- HER2-targeted therapy
- Breast cancer
- Cardiac dysfunction
- Cardiac safety
- Cardioprotective medications